MAPT and Alzheimer disease: Similarly, an extremely high dose of gosuranemab (Bristol-Myers Squibb/iPierian) specific to the N-terminal region of extracellular Tau (eTau) decreased over 90% eTau in the CSF in subjects with progressive supranuclear palsy19 and mild cognitive impairment due to AD or mild AD but unfortunately, showed no efficacy in both PASSPORT and TANGO trials20.